Concentrix CNXC
- Market cap
- $2B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.2×
- EV/EBIT
- 10.7×
- Revenue, 12 months
- $10B
- +3% on a year ago
- Net margin
- −24.0%
- Free cash flow yield
- 28.5%
Concentrix trades at 0.2× sales. Its trailing earnings are negative, so it has no PE. Revenue was $10B over the last twelve months, up 3% on a year earlier with a −24% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.2B+36% | $2.4B+47% | $2.4B+47% | $2.4B+46% | $2.4B+10% | $2.4B−1% | $2.4B+2% | $2.5B+4% | $2.6B+4% | $2.5B+5% | $2.5B+2% | $2.5B−1% | |
| Cost of revenue | $1.4B+34% | $1.5B+47% | $1.5B+47% | $1.5B+47% | $1.6B+12% | $1.5B−2% | $1.6B+3% | $1.6B+7% | $1.7B+6% | $1.7B+9% | $1.6B+5% | $1.6B−1% |
| Gross profit | $822.9M+39% | $856.5M+47% | $857.6M+48% | $864.2M+46% | $870.6M+6% | $855.9M−0% | $848.1M−1% | $855M−1% | $876M+1% | $849.7M−1% | $823.3M−3% | $848.9M−1% |
| SG&A | $642.4M+55% | $708.1M+67% | $707.4M+69% | $711M+65% | $726.1M+13% | $687M−3% | $699.8M−1% | $708M−0% | $730.6M+1% | $731.1M+6% | $727.9M+4% | $709.2M+0% |
| $180.4M+1% | $148.4M−5% | $150.2M−8% | $153.2M−6% | $144.5M−20% | $168.9M+14% | $148.3M−1% | $147M−4% | −$1.4B | $118.6M−30% | $95.4M−36% | −$910.3M | |
| Interest expense | $70.5M+151% | $82.4M+143% | $82.5M+75% | $80.8M+64% | $76.1M+8% | $73M−12% | $75.4M−9% | $72M−11% | $69.9M−8% | $75.3M+3% | $68.1M−10% | $64.9M−10% |
| Pre-tax income | $77.1M−53% | $72.8M−39% | $87.1M−18% | $26.4M−75% | $112.9M+46% | $100.8M+38% | $51.7M−41% | $111.4M+322% | −$1.4B | $28.7M−72% | $69.5M+34% | −$979.8M |
| $7.6M−87% | $20.7M−32% | $20.3M−25% | $9.8M−67% | −$2.7M | $30.5M+47% | $9.6M−53% | $23.3M+139% | $33.2M | $7.1M−77% | $14.2M+48% | $8.3M−64% | |
| Net income | $69.5M−34% | $52.1M−41% | $66.8M−15% | $16.6M−79% | $115.7M+66% | $70.3M+35% | $42.1M−37% | $88.1M+430% | −$1.5B | $21.6M−69% | $55.3M+31% | −$988.1M |
| $1.09−46% | $0.76−55% | $0.98−35% | $0.25−83% | $1.73+59% | $1.04+37% | $0.63−36% | $1.34+436% | −$23.74 | $0.33−68% | $0.86+37% | −$16.24 | |
| 61.9M+20% | 65.8M+28% | 65.3M+27% | 64.7M+26% | 64.4M+4% | 64.1M−3% | 63.4M−3% | 62.7M−3% | 62.1M−4% | 61.3M−4% | 60.9M−4% | 60.9M−3% |
EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY20 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Financial - Credit Services nearest Concentrix's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CNXCConcentrix | $2B | n/m | 14.0× | 0.2× | +3% | −24.0% | |
| WUWestern Union CO | $2B | 5.2× | 7.9× | 0.5× | −2% | 9.8% | |
| ECPGEncore Capital | $2.1B | 7.4× | 7.2× | 1.1× | +30% | 15.9% | |
| AGMFederal Agricultural Mortgage | $2.2B | 10.9× | 10.3× | 4.9× | +15% | 51.4% | |
| UPSTUpstart | $2.3B | 48.5× | 62.8× | 1.9× | +46% | 4.8% | |
| FLYWFlywire | $2.4B | 74.6× | 134× | 3.3× | +32% | 4.8% | |
| PAYOPayoneer Global | $2.4B | 47.7× | 28.4× | 2.2× | +6% | 4.6% | |
| EEFTEuronet Worldwide | $2.5B | 10.4× | 25.6× | 0.6× | +6% | 6.6% | |
| HAPNHappen | $1.6B | 8.5× | 20.6× | 1.6× | +18% | 18.7% | |
| PGYPagaya Technologies | $1.6B | 13.9× | 14.2× | 1.1× | +20% | 9.1% | |
| NUTXNutex Health | $1.4B | 8.3× | 11.0× | 1.7× | +7% | 21.2% | |
| Peer median | $2.1B | 10.6× | 17.4× | 1.6× | +17% | 9.4% |
More on Concentrix
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #6of 111Financial stocks with the highest free cash flow yield
- #10of 131Credit services stocks with the lowest price to sales ratio
- #6of 59Credit services stocks with the highest free cash flow yield
Its groups
About
- Industry
- Financial - Credit Services
- Sector
- Financial Services
Valuation data, not investment advice. Prices as of .